StaClear, Inc.

StaClear, Inc. manufactures specialized low-particulate single-use intravitreal syringes designed for ophthalmic drug delivery. The company's flagship product line addresses a critical clinical need: reducing silicone oil contamination in intraocular injections, a problem previously associated with floaters and elevated intraocular pressure when generic insulin syringes were used for intravitreal drug administration. StaClear offers three syringe configurations, all in 0.25 mL volume: - Attached Needle (SC250AN): pre-assembled with needle, ready-to-use - Luer Slip (SC250LS): compatible with standard ophthalmic needles via slip connection - Luer Lock (SC250LL): secure needle attachment via luer lock mechanism, available in both tray packs and unit packs The syringes feature a patented immobilized silicone coating anchored to syringe walls rather than liquid silicone oil, meeting USP <789> standards for low particulate matter. Engineered specifically for retina specialists, the design minimizes dead space to reduce drug wastage (saving up to $10–15 per injection), ensures precise dosing accuracy, and maintains elastomer piston sealing integrity. StaClear's SC250AN received FDA 510(k) clearance. All products carry CE marking and meet biocompatibility and chemical standards for ophthalmic use. The company was supported by NIH National Eye Institute SBIR grants during R&D and maintains strong relationships with retina practices, compounding pharmacies, outsourcing facilities, and ophthalmic pharmaceutical companies. Product guides and technical documentation available on the website.